MASSA, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 321
EU - Europa 203
AS - Asia 116
AF - Africa 45
Totale 685
Nazione #
US - Stati Uniti d'America 321
IT - Italia 81
SG - Singapore 65
SE - Svezia 56
CI - Costa d'Avorio 32
AT - Austria 25
CN - Cina 23
IN - India 16
BG - Bulgaria 13
GB - Regno Unito 12
SN - Senegal 7
NG - Nigeria 6
DE - Germania 5
PL - Polonia 5
TR - Turchia 5
HK - Hong Kong 3
VN - Vietnam 3
RO - Romania 2
CZ - Repubblica Ceca 1
FR - Francia 1
LK - Sri Lanka 1
NL - Olanda 1
UA - Ucraina 1
Totale 685
Città #
Chandler 55
Fairfield 37
Abidjan 32
Singapore 30
Vienna 25
Milan 20
New York 18
Santa Clara 18
Boardman 16
Seattle 15
Florence 14
Hyderabad 13
Sofia 13
Woodbridge 13
Wilmington 12
London 9
Lawrence 8
Princeton 8
Ann Arbor 7
Cambridge 7
Dakar 7
Pisa 7
San Diego 7
Lagos 6
Ashburn 5
Istanbul 5
Ogden 5
Quanzhou 5
Houston 4
Shanghai 4
Warsaw 4
Beijing 3
Cascina 3
Center 3
Frankfurt am Main 3
Hong Kong 3
Los Angeles 3
Medford 3
Santa Croce sull'Arno 3
Castiglione Chiavarese 2
Council Bluffs 2
Kent 2
Lucca 2
Norwalk 2
Philadelphia 2
Rome 2
Serra 2
Vicopisano 2
Bremen 1
Changsha 1
Formigine 1
Fort Worth 1
Fulham 1
Fuzhou 1
Garbagnate Milanese 1
Hangzhou 1
Marseille 1
Minneapolis 1
New Delhi 1
North Charleston 1
Olomouc 1
Pietrasanta 1
Redwood City 1
Stuttgart 1
Vicenza 1
Wuhan 1
Totale 489
Nome #
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 116
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 83
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 75
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 75
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 64
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 48
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 47
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 39
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 34
Equivalent efficacy but different safety profiles of gemcitabine plus nab-paclitaxel and folfirinox in metastatic pancreatic cancer 33
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 27
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 26
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 14
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 11
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 10
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 10
Totale 712
Categoria #
all - tutte 3.331
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.331


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202034 0 0 0 0 4 5 4 5 4 3 6 3
2020/202153 1 2 2 3 0 19 2 3 8 1 3 9
2021/202281 0 0 0 3 12 27 3 1 3 9 7 16
2022/2023250 18 33 18 11 28 33 2 25 62 0 16 4
2023/2024161 11 15 23 8 17 14 24 2 1 8 13 25
2024/2025117 1 33 20 39 24 0 0 0 0 0 0 0
Totale 712